COL9A1 and ovarian carcinoma: Collagen type IX alpha 1 (COL11A1) has emerged as not only a biomarker associated with poor clinical outcomes in ovarian cancer, but also an important molecular player that promotes ovarian cancer cisplatin resistance [8,9,10].